Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16792
Título
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Autor(es)
Rose, Angela Mc | Nicolay, Nathalie | Sandonis-Martin, Virginia ISCIII | Mazagatos, Clara ISCIII | Petrović, Goranka | Niessen, F Annabel | Machado, Ausenda | Launay, Odile | Denayer, Sarah | Seyler, Lucie | Baruch, Joaquin | Burgui, Cristina | Loghin, Isabela I | Domegan, Lisa | Vaikutytė, Roberta | Husa, Petr | Panagiotakopoulos, George | Aouali, Nassera | Dürrwald, Ralf | Howard, Jennifer | Pozo Sanchez, Francisco ISCIII | Sastre-Palou, Bartolomé | Nonković, Diana | Knol, Mirjam J | Kislaya, Irina | Luong Nguyen, Liem Binh | Bossuyt, Nathalie | Demuyser, Thomas | Džiugytė, Aušra | Martínez-Baz, Iván | Popescu, Corneliu | Duffy, Róisín | Kuliešė, Monika | Součková, Lenka | Michelaki, Stella | Simon, Marc | Reiche, Janine | Otero-Barrós, María Teresa | Lovrić Makarić, Zvjezdana | Bruijning-Verhagen, Patricia Cjl | Gomez, Verónica | Lesieur, Zineb | Barbezange, Cyril | Van Nedervelde, Els | Borg, Maria-Louise | Castilla, Jesús | Lazar, Mihaela | O'Donnell, Joan | Jonikaitė, Indrė | Demlová, Regina | Amerali, Marina | Wirtz, Gil | Tolksdorf, Kristin | Valenciano, Marta | Bacci, Sabrina | Kissling, Esther | MOVECOVID- 19 hospital study team | VEBIS hospital study team
Fecha de publicación
2023-11
Cita
Euro Surveill. 2023 Nov;28(47):2300186.
Idioma
Inglés
Tipo de documento
research article
Resumen
Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
Palabras clave
MESH
COVID-19 | Humans | Adult | BNT162 Vaccine | RNA, Viral | SARS-CoV-2 | Vaccine Efficacy | Hospitalization | Europe
Versión en línea
DOI
Aparece en las colecciones
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- VaccineEffectivenessAgainstCOV ...
- Tamaño:
- 764.6Kb
- Formato:
- Descripción:
- Articulo
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Supplementary_VaccineEffective ...
- Tamaño:
- 378.9Kb
- Formato:
- Descripción:
- supplementary material